搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
16 天
肿瘤免疫疗法十年:PD-1与创新陷阱
九年前,莉萨·海恩斯(Lisa Haines)悲观地得知,她之前通过化疗抑制的肺癌又复发了。正当这名患者准备接受现实,主治医生推荐了一种免疫疗法,Opdivo。
Targeted Oncology
4 天
FDA Approves New Dosage of Trastuzumab Biosimilar for HER2-Overexpressing Cancers
Following its initial approval at 150 mg, trastuzumab-strf has also been approved at 420 mg for the treatment of several HER2 ...
13 天
新研究可阻断乳腺癌细胞向大脑转移
当乳腺癌扩散到大脑时,会导致严峻的后果,患者通常只有六个月的生命。临床统计表明,HER2阳性乳腺癌女性在多达55%的病例中倾向于发生脑转移。针对脑转移的乳腺癌细胞,目前化学疗法药物通常无效,因为它们无法穿越血脑屏障。
oncnursingnews
17 天
Longer Duration of Adjuvant Trastuzumab May Further Improve DFS Rates in ERBB2-Positive ...
Adjuvant trastuzumab reveals associations with improved disease-free survival in 1-year vs 9-week administration of the drug ...
Pharmaceutical Technology on MSN
4 天
FDA approves Accord BioPharma’s HERCESSI for cancer treatment
Accord BioPharma received FDA approval for 420mg HERCESSI, a biosimilar to Herceptin to treat various kinds of ...
The Punch Newspapers
1 天
22-year-old LASU student battles cancer, family seeks N15m financial help
A 22-year-old LASU student is urgently seeking N15 million financial assistance as she battles an aggressive form of breast ...
Health on MSN
3 天
Does Adjuvant Therapy Prevent Cancer Recurrence?
"Neoadjuvant therapy” refers to supplemental cancer treatment you receive before your primary treatment. Adjuvant therapies, ...
Cure Today
9 天
TILs May Predict Survival in Early HER2-Positive Breast Cancer Treated With Herceptin
High TILs may predict which patients with early HER2-positive breast cancer may have a reduced risk for disease relapse or ...
Targeted Oncology
6 天
Tumor-Infiltrating Lymphocytes as Potential Predictors of Survival in Trastuzumab-Treated ...
In a 10-year analysis of the ShortHER trial, high tumor-infiltrating lymphocytes were associated with improved survival in ...
FierceBiotech
7 天
ESMO: Jazz HER2 bispecific posts 59% survival at 30 months in gastric cancer
Jazz Pharmaceuticals has posted fresh phase 2 data on zanidatamab that show the HER2-targeted bispecific antibody kept 59% of ...
7 天
on MSN
Monoclonal antibodies offer hope for tackling antimicrobial resistance
Monoclonal antibodies—treatments developed by cloning a cell that makes an antibody—could help provide an answer to the ...
eLife
7 天
CausalXtract: a flexible pipeline to extract causal effects from live-cell time-lapse ...
Live-cell microscopy routinely provides massive amount of time-lapse images of complex cellular systems under various physiological or therapeutic conditions. However, this wealth of data remains ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果
反馈